Ajanta Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · India · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Ajanta Tower 54-a M Vasanji Chakala Andh...Phone Number
+91 2266061000Website
www.ajantapharma.comRevenue
$557.5 MillionStock Symbol
AJANTPHARMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Ajanta Pharma
Ajanta Pharma is an Indian multinational pharmaceutical company that develops, manufactures, and markets a broad range of branded and generic pharmaceutical products for both domestic and international markets. The company’s portfolio spans multiple therapeutic areas, including cardiology, dermatology, anti‑infectives, pain management, and ophthalmology, with products distributed through its own sales and marketing networks as well as through partnerships. Ajanta Pharma focuses on research, regulatory compliance, and quality manufacturing to support access to affordable medicines, while also expanding its presence in global markets across Asia, Africa, and other regions. The company’s operations encompass formulation development, compliance with international standards, and strategic market expansion to serve diverse healthcare needs.Explore more
Ajanta Pharma Org Chart
SA
President
PV
President
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ajanta Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Ajanta Pharma is spiking on competitors!
Ajanta Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Ajanta Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ajanta Pharma recently announced quarterly report
Product Launch: Get notified when Ajanta Pharma launches new products
Click to see if Ajanta Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Ajanta Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ajanta Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Explore company insights
Get a deeper look into Ajanta Pharma's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Ajanta Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ajanta Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ajanta Pharma.
Ajanta Pharma Tech Stack
A closer look at the technologies used by Ajanta Pharma
See more technologies
Most Recent Scoops
Earnings
Ajanta Pharma has reported growth of 15% per IQVIA MAT June 2026 data, outperforming the Indian Pharmaceutical Market's growth of 11%, with volume growth 40% higher than the IPM and new product launch growth exceeding the market by 75%.
Product Launch, Pharmaceuticals
Earnings
Ajanta Pharma has reported adjusted EBITDA of INR 454 crore for Q1 FY2027, an increase of 21% compared with INR 371 crore in the corresponding quarter last year, with a margin of 28%, and full-year EBITDA margin guidance maintained at approximately 27% with a variation of 100 basis points.
Earnings, Finance
Earnings
Ajanta Pharma has reported personnel costs of INR 381 crore for Q1 FY2027, an increase of 26% compared with INR 303 crore in the corresponding quarter last year, primarily attributable to annual increments and headcount additions made in the previous year.
Hiring Plans, Compensation & Benefits, HR Operations
Earnings
Ajanta Pharma has reported Africa Institutional business sales of INR 49 crore for Q1 FY2027, an increase of 70% compared with INR 28 crore in the corresponding quarter last year, contributing approximately 4% to total company revenue.
Sales
Earnings
Earnings, Research & Development, Finance
Ajanta Pharma News & Media
Ajanta Pharma promoter entities sell 4.3% stake for Rs 637 crore
Promoter entities of Ajanta Pharma on Thursday divested 4.3 per cent stake in the company for Rs 637 crore through open market transactions. The buyers included over two dozen funds such as UTI Mutual Fund (MF), Aditya Birla Sun Life MF, Franklin Templeton MF, ICICI Prudential MF, Mirae Asset MF, Abu Dhabi Investment Authority and Tata AIA Life Insurance Company, among others. Aayush Agrawal Trust and Ravi Agrawal Trust offloaded a total of 54,92,846 shares,Ajanta Pharma board approves up to Rs 286-crore share buyback plan
Drug firm Ajanta Pharma said its board has approved a share buyback plan of up to Rs 286-crore, wherein the drug maker will buy back shares at a maximum price of Rs 2,550 apiece.Dementia Drugs Market Value Anticipated To Reach Around US$ 24.7 Billion By 2027: Acumen Research And Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Dementia Drugs Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027” LOS ANGELES, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The Global Dementia Drugs Market is anticipated to grow at a CAGR of around 8.5% during the forecast period 2020 to 2027 and to reach around US$ 24.7 Bn by 2027. Rising number of patients suffering from dementia
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ajanta Pharma
Sign Up For FreeTo access detailed company insights
Ajanta Pharma is an Indian multinational pharmaceutical company that develops, manufactures, and markets a broad range of branded and generic pharmaceutical products for both domestic and international markets. The company’s portfolio spans multiple therapeutic areas, including cardiology, dermatology, anti‑infectives, pain management, and ophthalm... Read More
